Operation
TrialBlazer is the United States Department of Health and
Human Services (HHS)’ coordinated
roadmap for strengthening early clinical research. Announced on June 22, 2026,
it covers phase-appropriate Investigational New Drug (IND) requirements,
real-world data (RWD), new approach methodologies (NAMs), decentralized trials,
master protocols, and interoperable health data. For sponsors, the central
message is clear: HHS is pursuing shorter development timelines while
maintaining regulatory oversight, participant protection, and data integrity (HHS Roadmap, 2026).
What Related Actions Have Been Announced?
HHS
frames Operation TrialBlazer as a coordinated response to global competition
and domestic startup delays. The roadmap notes that China
registered more than 7,100 clinical trials in 2024, or 39% of the global total.
In the United States, the average interval between a pre-IND meeting request
and IND submission is 380 days, while Institutional Review Board (IRB) review
and contracting can add up to 13 months.
1. U.S. Food
and Drug Administration (FDA): Accelerate first-in-human studies and reduce
administrative delay.
● Phase-appropriate
IND requirements: The FDA is clarifying chemistry, manufacturing, and
controls (CMC), pharmacology/toxicology, and protocol expectations for
first-in-human (FIH) studies. The agency estimates that focusing on necessary
Phase I information may save six to 12 months.
● Expedited IND
Pilot Program: Participating sponsors may work with qualified research
institutions (QRIs) and submit IND components for rolling review. Sponsors
retain IND ownership, while the FDA retains regulatory authority.
● Later-stage
development and access: The FDA is considering a single IRB model for
multisite research. Revised draft guidance addresses one adequate and
well-controlled trial plus confirmatory evidence and basket, umbrella, and
platform master protocols. HHS also plans work on participation barriers and
embedding randomized controlled trials (RCTs) in routine care.
● Sponsor support: The FDA provides
a Phase 1 IND Navigator, a Phase 1 CMC resource, and a contact center (FDA, 2026). HHS also
plans stakeholder roundtables on IND processes, IRB review, contracting, and
payment uncertainty.
2. National Institutes of Health (NIH):
Improve trial performance, evidence use, and access.
● The NIH plans to
define success metrics, issue a request for information on trial performance,
expand reusable clinical and regulatory playbooks, and increase use of the
Streamlined, Multisite, Accelerated Resources for Trials (SMART) IRB reliance
platform.
● It also plans to
examine RWD and causal inference for feasibility, recruitment, and evidence
generation; advance NAMs; update data and safety monitoring policies; and
support decentralized and hybrid trials in community and rural settings.
3. Advanced Research Projects Agency
for Health (ARPA-H): Support alternative models and complex therapies.
● Predictive human
and computational models may reduce reliance on animal testing where
scientifically appropriate and improve preclinical safety assessment.
● Platform and
umbrella trials may support genetic medicines, while computational and
artificial intelligence tools may improve advanced-therapy manufacturing
consistency, scalability, batch control, and outcome prediction.
4. Office of the National Coordinator
for Health Information Technology (ONC): Strengthen digital matching and
protocol reuse.
● ONC is exploring
links between certified electronic health records (EHRs) and the
ClinicalTrials.gov public application programming interface. The roadmap
reports certified EHR adoption of approximately 99% among hospitals and 90%
among providers.
● ONC also supports
computable protocol standards, including International Council for
Harmonisation (ICH) M11/ceSHarP, the Clinical Data Interchange Standards
Consortium (CDISC) Unified Study Definitions Model, and the Health Level Seven
(HL7) Fast Healthcare Interoperability Resources (FHIR)-based Clinical Study
Protocol.
* Implementation
remains mixed. The roadmap combines launched programs with draft guidance,
contemplated rulemaking, planned data work, and exploratory initiatives.
What Role Can a CRO Play Amid These Changes?
A contract research organization (CRO) can help convert
policy direction into an executable development plan. The underlying problem is
fragmentation: regulatory, CMC, nonclinical, clinical, site, and data teams may
work to different assumptions or timelines. The resulting
gaps can cause unnecessary studies, sequential reviews, protocol amendments, or
delayed site activation.
Depending
on its capabilities and the agreed scope of work, a CRO may provide support in
the following areas:
| Service Area | Services a CRO can Provide | Key Sponsor Decisions |
|---|
| Development strategy and regulatory support | Assess
development gaps and support development planning, submission strategies, and
regulatory communication plans. | Define
development objectives, target markets, budget, and acceptable risks. |
| Clinical trial design | Support
protocol development, endpoint selection, sample size estimation, and
statistical analysis planning. | Approve
study objectives, target populations, key endpoints, and trial design. |
| Trial startup and operations | Select
study sites and coordinate ethics submissions, contracts, participant
recruitment, and trial execution. | Approve
the site strategy, recruitment plan, resource allocation, and major changes. |
| Data management and statistical analysis | Develop
study databases, validate and clean data, perform statistical analyses, and
summarize results. | Approve
data standards, access permissions, and the statistical analysis plan. |
| Safety and quality management | Support
safety information processing, clinical monitoring, quality checks, and
corrective actions. | Evaluate
significant safety and quality issues and approve risk controls and response
measures. |
| Medical writing and submission preparation | Prepare
or compile investigator’s brochures, clinical study reports, and other
submission documents. | Review
key scientific conclusions and approve final documents and submission content. |
Note: The specific scope of
services and each party’s responsibilities should be defined according to
project needs and written agreements.
Explore More:
Preclinical
CRO Selection Guide: How Cross-Regional Lab Networks Support IND-Enabling
Studies
Decentralized
Clinical Trials: From Technology Adoption to Patient-Centric Design
The
Role of Global Regulatory Affairs in Clinical Development
How Can Companies Prepare for an Evolving Clinical
Research Landscape?
As a global contract research organization, Tigermed
integrates scientific, regulatory, operational, and data expertise across the
full development lifecycle. This helps sponsors make evidence-based decisions
early and develop plans designed to withstand regulatory and operational
review.
Against the backdrop of evolving initiatives such as
Operation TrialBlazer, Tigermed’s relevant strengths include real-world data (RWD),
methods that may reduce reliance on animal testing where scientifically
appropriate, decentralized and hybrid clinical trial
models, and CMC support
for advanced therapies. Together, these capabilities may help
reduce avoidable rework, manage cross-functional risks, and keep development
plans aligned as requirements evolve.
Learn more about how Operation TrialBlazer may affect
early-development strategy, compliance planning, and program execution. Contact Tigermed to
discuss your program needs.
References
[1] United States
Department of Health and Human Services. Operation TrialBlazer: HHS Roadmap
to Maintaining U.S. Leadership in Early Clinical Research and Development.
2026.
[2] United States
Department of Health and Human Services. HHS Launches Unprecedented
Department-Wide Effort to Restore American Leadership in Clinical Trials.
June 22, 2026.
[3] U.S.
Food and Drug Administration. FDA Actions to Accelerate and Modernize
Early and Late-Stage Clinical Development. 2026.
